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Method. A 9-year-old female patient presented in June 2009 with vomiting and headache. Cranial CT and MRI:
hypothalamic–chiasmatic tumor extending into the left cerebral peduncle and hippocampus with cerebellar folia distortion,
affecting both hemispheres and vermis suggestive of low-grade glial tumor. Began chemotherapy treatment in December 2009.
MRI (February 2010): increased lesion. Patient is referred in April 2010 for RT.
Results. The patient received a dose of 50.4Gy at 1.8/day in tumor region by four isocentric ﬁelds with energies of 6 and 15mV. Sub-
sequently boosted from previous volume to 54Gy. MRI (June 2010): practical resolution of the tumor. October 2010: disconnection
from environment with staring, rigidity, loss of urinary sphincter control. CT brain: hydrocephalus. Ventriculoperitoneal shunt
was placed. MRI (February 2011): diffuse pachyleptomeningitis suggesting leptomeningeal carcinomatosis Vs infection. With
suspicion of TB, tuberculostatic treatment was administered. March 2011: brain biopsy was performed: WHO grade III anaplastic
oligodendroglioma. Temozolomide treatment was initiated with progression in December 2011. She died on May 2012.
Conclusions. The doses in brain tumors have been of 45–60Gy with fractionation of 1.8Gy, but a phase III prospective, randomized
EORTC study showed that low-grade OPG show no relationship between radiation dose and tumor response because it is normal
to stay in the lower limit of said range (45–50Gy). The use of RTEF and IMRT achieve a good rate of compliance and help reduce
radiation volumes, achieving the same results with less toxicity, obtaining similar clinical outcomes except for comprehensive
doses whose possible deleterious effects are yet to be speciﬁed.
http://dx.doi.org/10.1016/j.rpor.2013.03.138
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Introduction. Papillary tumors of the pineal region (PTPR) were recognized as a distinct entity in the 2007 (WHO). Clinical presenta-
tion includes headache and obstructive hydrocephalus and it is frequent local recurrences. The treatment remains controversial.
Objective. A case of PTPR and its multidisciplinary treatment.
Case report. We describe a case of PTPR in a 54 year-old male who presented giddiness and headache of 2 years duration. Mag-
netic resonance imaging (MRI) showed an extraaxial and heterogeneous pineal gland lesion measuring 2 cm×0.9 cm×0.5 cm
with associated obstructive hydrocephalus. An endoscopic third ventriculostomy was performed followed by subtotal resection.
Histologically, the tumor was composed of polygonal cells, arranged in solid sheets with multilayered papillary architecture.
The predominant population of tumor cells showed esoinophilic cytoplasm. The tumor cells were immunoreactive for vimentin,
CAM5.2, CK18 and AE1/AE3, but negative for (GFAP). Ki67:4%. Two months later, the patient went to the emergency service with
an alteration to the march, drowsiness and vomiting. The CT scan showed a clear increase in the ventricular size reason why
is performed a ventricular–peritoneal derivation, with an adequate control of symptoms and of the obstructive hydrocephalus.
The post-surgery MRI revealed a 1.3 cm×0.7 cm residual tumor. The neuro-oncology group decided to give local radiation of
54Gy/2Gy.
Results. The MRI revealed no changed in residual tumor and complete resolution of the hydrocephalus. The patient has a left
temporal hemianopsy and is in follow-up.
Discussion PTPR is considered as a separate entity from plexus papilloma, differentiated by the expression of cytokeratins, the
CK18 associated with PTPR and with the ependymoma has a strong immunoreactivity to GFAP difference with PTRP who is
absent. The total resection was the factor strongly associated with overall survival and recurrence. The requirement of radiation
after total resection with no aggressive histology is an alternative treatment approach that may result in high local control.
http://dx.doi.org/10.1016/j.rpor.2013.03.139
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Introduction. The patterns of failure in patients (pats) with glioblastoma (GB) treated with conventional treatment are predomi-
nantly local (80–90%). Few studies have evaluated the patterns of recurrence using IMRT in patients with GB.
Material and methods. Patswith pathological diagnosis of GBwere included in a prospective study. Treatment consisted ofmaximal
surgical resection using 5-ALA-guided surgery, postop-IMRT with concomitant-temozolamide (TMZ) and adjuvant-TMZ. Target
volumes were outlined using trimodal image fusion with (CT/11C-MET-PET/MR). GTV was deﬁned as the surgical cavity plus the
residual disease observed in CT/11C-MET-PET/MR images. CTV included the GTV plus 2-cm margin and the PTV was generated
after 0.3–0.5-cm expansion of the CTV. Prescription doses were 70Gy, 65Gy and 60Gy to the 95% of the GTV, CTV and PTV,
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respectively. MRI-images of tumor recurrences were fused with the original planning-CT, and patterns of failure were deﬁned
according to the location of recurrence respect the isodose lines (IDL). Central recurrences were deﬁned when the recurrence
was located within the 65Gy-IDL, local recurrence in the 55–60Gy-IDL, marginal recurrence in the 30–50Gy-IDL and distal failure
when the recurrence was located outside the 30Gy-IDL.
Results. From January 2007 to May 2012, 48 pats with a MFU of 39.12 months (9–73 months) were enrolled in the study. Twenty-
two pats (44.9%), 2-pats (4.1%), 0-pats (0%), 4-pats (8.2%) and 7-pats (14.3%) had central, local, marginal, central plus local and
distal recurrences, respectively. Local–central control was achieved in 19-pats (42%). Central recurrences were more frequently
observed in pats with unmethylated-MGMT (13/19 pats, 68%). Median OS and PFS were 21 months and 14 months, respectively.
Conclusions. In this series, the patterns of failure in GB were predominantly local–central (50%). Using 11C-MET-PET planning
images and highly conformal dose distribution, we have not observed an increase in marginal recurrences rates. Patients with
unmethylated-MGMT tumors have more local–central recurrences. Future studies with the inclusion of a greater number of pats
are warranted to conﬁrm these data.
http://dx.doi.org/10.1016/j.rpor.2013.03.140
Patterns of relapse in glioblastoma after neoadjuvancy and radiation therapy
S. Comas1, S. Villà1, O. Etxaniz2, S. Domènech3, C. Hostalot4, C. Carrato5, C. Bugès6, C. Balan˜á7
1 H. Universitari Germans Trias I Pujol, Oncologia Radioterapica, Spain
2 H. Universitari Germans Trias I Pujol, Oncologia Medica, Spain
3 H. Universitari Germans Trias I Pujol, Radiologia, Spain
4 H. Universitari Germans Trias I Pujol, Neurocirugía, Spain
5 H. Universitari Germans Trias I Pujol, Anatomia Patologica, Spain
6 H. Universitari Germans Trias I Pujol, Oncologia Médica, Spain
7 H. Universitari Germans Trias I Pujol, Spain
Purpose. To determine, at ﬁrst progression, if patients receiving anti-VEGF show different patterns of relapse compared with
patients treated with conventional concomitant RT/CT.
Methods. Patients fromour center included in a prospective trial designed for neoadjuvant treatment in only biopsied glioblastoma
patients are analyzed. All GD-enhanced T1 and FLAIR MRI sequences were reviewed and co-registered with treatment planning
done just before radiotherapy. Patterns of relapse after radiotherapy were deﬁned as follows: A. all relapses were within the
95% of isodose; B. all relapses were between 95% and 50% of isodose; C. all relapses were outside 50% of isodose. Two groups of
patients were included; those treated with temozolamide (TMZ) alone (TMZ group) before radiotherapy and those who received
neoadjuvant TMZ and Bevacizumab (BV) (TMZ+BV group).
Results. Nineteen patients are included at ﬁrst analysis. Thirteen had progressed after complete radiation (RDT) treatment and
were available for evaluation (4 in TMZ group and 9 in TMZ+BV group). Mean time to progression after RDT was 150 days in
TMZ-group and 151.8 days in TMZ+BV group. GD-enhanced T1 did not show differences in patterns of relapse between both
groups, being the pattern A the most common (100% in TZM group vs 88.8% in TMZ+BZM group). However, FLAIR sequence
showed more B and C patterns in both groups. A–C patterns were observed in 25%, 75% and 0% in TMZ group; and 33.3% for each
pattern in TMZ+BV group. Results showed a trend to detect more C patterns of relapse in patients who had received anti-VEGF
treatment.
Conclusions. These results show that FLAIR sequence is essential in deﬁning the patterns of relapse in patients treated with
neoadjuvant treatment. Sample will be updated at presentation. Deﬁning patterns of relapse with new drugs could be deﬁnitive
for radiotherapy volumes and doses.
http://dx.doi.org/10.1016/j.rpor.2013.03.141
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Introduction. Anaplastic oligodendroglioma is a malignant brain tumor uniquely sensitive to treatment with both chemotherapy
and radiotherapy. There are few prospective clinical trials for newly diagnosed patients and multiple approaches to the treatment
of these patients. This review is an analysis of our patients with anaplastic oligodendroglioma and oligoastrocytoma.
Material and methods. We have reviewed the treatment results in 12 patients, ten with intracranial anaplastic oligodendroglioma
and two with anaplastic oligoastrocytoma, treated from 2007 through 2012 at the Hospital General de Ciudad Real. Ten patients
received adjuvant radiotherapy with median dose of 60Gy and concomitant Temozolamide and two treated with RTOG BR0103
scheme. The median age was 45 years old. Eleven patients had determined the co-delection 1p19q, 2 of them had a negative 1p,
one had negative 1p19q and the rest, had a co-deletion.
